KZR Logo

Kezar Life Sciences, Inc. (KZR) 

NASDAQ
Market Cap
$55.31M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
363 of 774
Rank in Industry
199 of 432

Largest Insider Buys in Sector

KZR Stock Price History Chart

KZR Stock Performance

About Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products …

Insider Activity of Kezar Life Sciences, Inc.

Over the last 12 months, insiders at Kezar Life Sciences, Inc. have bought $0 and sold $3,879 worth of Kezar Life Sciences, Inc. stock.

On average, over the past 5 years, insiders at Kezar Life Sciences, Inc. have bought $9.65M and sold $1.31M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 20,000 shares for transaction amount of $295,400 was made by BERGER FRANKLIN M () on 2022‑03‑18.

List of Insider Buy and Sell Transactions, Kezar Life Sciences, Inc.

2024-07-02SaleChief Legal Officer
6,688
0.0084%
$0.58$3,879+11.23%
2023-02-06Sale10 percent owner
40,000
0.0558%
$6.88$275,320-69.99%
2023-02-03Sale10 percent owner
25,000
0.0348%
$7.15$178,650-70.14%
2023-02-02Sale10 percent owner
50,000
0.0681%
$7.19$359,500-70.86%
2023-02-01Sale10 percent owner
40,000
0.0558%
$6.95$278,000-68.99%
2023-01-31Sale10 percent owner
30,000
0.041%
$7.08$212,400-70.01%
2023-01-30Sale10 percent owner
30,000
0.041%
$6.91$207,300-68.71%
2023-01-25Saledirector
50,000
0.0697%
$6.85$342,500-67.35%
2023-01-24Saledirector
80,000
0.1103%
$6.98$558,400-68.05%
2023-01-23Saledirector
80,000
0.1109%
$6.81$544,800-66.76%
2023-01-17Saledirector
6,114
0.0088%
$6.79$41,514-64.18%
2023-01-13Saledirector
1,971
0.0029%
$7.15$14,093-65.50%
2023-01-12Saledirector
5,000
0.0068%
$6.77$33,850-65.80%
2023-01-06Saledirector
3,000
0.0042%
$6.89$20,670-65.20%
2023-01-05Saledirector
12,162
0.017%
$6.97$84,769-65.51%
2023-01-04Saledirector
30,000
0.0414%
$7.17$215,100-66.90%
2023-01-03Saledirector
500
0.0007%
$7.10$3,550-65.66%
2022-12-29Saledirector
25,000
0.0375%
$7.10$177,500-66.15%
2022-10-04Saledirector
3,612
0.0056%
$8.82$31,857-64.16%
2022-10-03Saledirector
28,700
0.0425%
$8.78$251,957-65.34%

Insider Historical Profitability

10.68%
Equal Talent Investments Ltd10 percent owner
6254545
85.7231%
$7.5810+13.64%
Morningside Venture Investments Ltd10 percent owner
5447993
74.6687%
$7.58219+42.12%
Cormorant Asset Management, LP10 percent owner
1572909
21.5579%
$7.5810+15.16%
BERGER FRANKLIN M
890691
12.2076%
$7.5840+11.46%
BAY CITY CAPITAL LLC10 percent owner
622229
8.5281%
$7.5810+15.16%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Suvretta Capital Management, LLC$6.46M9.857.17M0%+$00.27
Avidity Partners Management Lp$4.53M6.95.03M+0.01%+$492.270.17
BlackRock$4.16M6.344.62M-4.16%-$180,570.67<0.0001
The Vanguard Group$2.79M4.253.09M+1%+$27,715.19<0.0001
Sphera Fund$1.85M2.822.05M0%+$00.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.